详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Cancer Institute and Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin/CN, [2]Harbin Medical University, Cancer Hospital, Heilongjiang,/CN, [3]Fudan University, Zhongshan Hospital, Shanghai/CN, [4]The Fourth Military Medical University, Tangdu Hospital, Xi’An Hospital, Xi’An/CN, [5]The First Hospital, Qing Dao University, Qingdao/CN, [6]Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai/CN, [7]Fujian Medical University Union Hospital, Fujian/CN, [8]Zhejiang Cancer Hospital, Hangzhou/CN, [9]The First Bethune Hospital of Jilin University, Changchun/CN, [10]Tumor Hospital of Hebei Province, Shijiazhuang, Shijiazhuang/CN, [11]Cancer Hospital, Sun Yat-Sen University, Guangzhou/CN, [12]The First Affiliated Hospital of Suzhou University, Jiangsu/CN, [13]Sichuan Cancer Hospital & Institute, Chengdu/CN, [14]Peking University Cancer Hospital, Beijing, Beijing/CN, [15]Liaoning Cancer Hospital, Shenyang, Tianjin/CN, [16]Fudan University, Shanghai Cancer Center, Shanghai/CN

出处：

DOI：

ISSN：

关键词： Adjuvant therapy Erlotinib EGFR mutation

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2017]版：

Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 10.34 出版当年[2017版] 7.296 出版当年五年平均 6.595 出版前一年[2016版] 12.46 出版后一年[2018版]

第一作者：

第一作者机构： [1]Cancer Institute and Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin/CN,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients [2]Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial [3]Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations [4]A PROSPECTIVE, MOLECULAR EPIDEMIOLOGICAL STUDY OF EGFR MUTATIONS IN ASIAN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH ADENOCARCINOMA HISTOLOGY (PIONEER STUDY) - CHINA SUBSET ANALYSIS [5]Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study [6]中国最大样本量探索EGFR非常见突变肺癌的预后和治疗模式 [7]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [8]Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC [9]Efficacy of EGFR-TKIs for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports [10]Investigation of RBM10 mutation and its associations with clinical and molecular characteristics in EGFR-mutant and EGFR-wildtype lung adenocarcinoma